Sanofi (SNY) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $105.16B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | FR | CEO | Belén Garijo López |
| IPO Date | 2002-07-01 | CAGR | 8.69% |
| Employees | 82,878 | Website | www.sanofi.com |
| Div. Yield | 8.29% | Payout Ratio | 46% |
| Buy Back Yield | 0.03% | Total Yield | 8.32% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $113.36B | P/E | 9.44 | Forward P/E | 8.43 | PEG | -1.64 |
| P/S | 1.02 | P/B | 0.82 | P/CF | 2.94 | P/FCF | 3.17 |
| Sales | $55.02B | Sales 1Y | 8.18% | Sales 3Y | 2.5% | Sales 5Y | 28.2% |
| EPS | $4.59 | EPS 1Y | -27.51% | EPS 3Y | -41.62% | EPS 5Y | -59.96% |
| Sales QoQ | -7.87% | EPS QoQ | -145.89% | Sales QoQ Avg | 2.17% | EPS QoQ Avg | -73.05% |
| Gross Margin | 71.62% | Operating Margin | 25.09% | Profit Margin | 17.59% | ROCE | 15.07% |
| ROA | 8% | ROE | 14% | Altman Z Score | 1.6 | Piotroski Score | 6 |
| Current Ratio | 1.01 | Quick Ratio | 0.22 | Cash Ratio | 0.18 | Op. CF Ratio | 0.11 |
| Debt/Equity | 0.27 | Debt/Assets | 0.16 | Lt Debt/Equity | 0.19 | Lt Debt/Cap. | 0.14 |
| Intrst Cov. | 27.98 | Inventory Turnover | 0.71 | Asset Turnover | 0.46 | Receivables Turnover | 122.17 |
| Enterprise Value | $113.36B | P/E Ratio | 9.44 |
| Forward P/E | 8.43 | PEG Ratio | -1.64 |
| P/S Ratio | 1.02 | P/B Ratio | 0.82 |
| P/CF Ratio | 2.94 | P/FCF Ratio | 3.17 |
| EPS | $4.59 | EPS Growth 1Y | -27.51% |
| EPS Growth 3Y | -41.62% | EPS Growth 5Y | -59.96% |
| Revenue Growth 1Y | 8.18% | Gross Margin | 0.72% |
| Operating Margin | 0.25% | Profit Margin | 0.18% |
| ROE | 0.14% | ROA | 0.08% |
| ROCE | 0.15% | Current Ratio | 1.01 |
| Quick Ratio | 0.22 | Cash Ratio | 0.18 |
| Debt/Equity | 0.27 | Interest Coverage | 27.98 |
| Altman Z Score | 1.6 | Piotroski Score | 6 |
Sanofi (SNY) valuation & financials
Sanofi (SNY) has a market capitalization of $105.16B and trades at a price-to-earnings ratio of 9.4. It operates in the Healthcare sector (Drug Manufacturers - General).
Sanofi's revenue grew +8.2% over the last year.
Sanofi's next earnings report is scheduled for July 30, 2026 before market open; analysts estimate EPS of $1.09.
Sanofi (SNY) — frequently asked questions
When does Sanofi (SNY) report earnings next?
Sanofi is expected to report earnings on July 30, 2026 before market open. Analysts estimate EPS of $1.09.
What is Sanofi's market cap?
Sanofi (SNY) has a market capitalization of $105.16B.
What is SNY's P/E ratio?
Sanofi trades at a price-to-earnings ratio of 9.4, with trailing twelve-month EPS of $4.59.
How fast is Sanofi growing?
Sanofi's revenue grew +8.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)